MA32099B1 - Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci - Google Patents

Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci

Info

Publication number
MA32099B1
MA32099B1 MA33112A MA33112A MA32099B1 MA 32099 B1 MA32099 B1 MA 32099B1 MA 33112 A MA33112 A MA 33112A MA 33112 A MA33112 A MA 33112A MA 32099 B1 MA32099 B1 MA 32099B1
Authority
MA
Morocco
Prior art keywords
composition
antibody binding
acidic variants
her2
her2 domain
Prior art date
Application number
MA33112A
Other languages
Arabic (ar)
English (en)
Inventor
Reed J Harris
Paul A Motchnik
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40672664&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32099(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA32099B1 publication Critical patent/MA32099B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition comprenant, comme composant principal, un anticorps anti-her2 se liant au domaine ii de her2, ainsi que des variantes acides de celle-ci. L'invention concerne également des formes pharmaceutiques comprenant ladite composition, ainsi que les utilisations thérapeutiques de celle-ci.
MA33112A 2008-01-30 2010-08-23 Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci MA32099B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2482508P 2008-01-30 2008-01-30
PCT/US2009/032220 WO2009099829A1 (fr) 2008-01-30 2009-01-28 Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci

Publications (1)

Publication Number Publication Date
MA32099B1 true MA32099B1 (fr) 2011-02-01

Family

ID=40672664

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33112A MA32099B1 (fr) 2008-01-30 2010-08-23 Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci

Country Status (37)

Country Link
US (8) US8652474B2 (fr)
EP (3) EP4119583A1 (fr)
JP (2) JP5933179B2 (fr)
KR (1) KR101223941B1 (fr)
CN (1) CN101981056B (fr)
AR (2) AR070276A1 (fr)
AU (1) AU2009210545C1 (fr)
BR (1) BRPI0905733B8 (fr)
CA (1) CA2711798C (fr)
CL (1) CL2009000178A1 (fr)
CO (1) CO6231039A2 (fr)
CR (2) CR11648A (fr)
CY (2) CY1120191T1 (fr)
DK (2) DK3401335T3 (fr)
EC (1) ECSP10010433A (fr)
ES (2) ES2668680T3 (fr)
HK (1) HK1151543A1 (fr)
HR (2) HRP20211469T1 (fr)
HU (2) HUE055108T2 (fr)
IL (2) IL206931A (fr)
LT (2) LT3401335T (fr)
MA (1) MA32099B1 (fr)
MX (1) MX2010008035A (fr)
MY (1) MY158560A (fr)
NO (1) NO2238172T3 (fr)
NZ (1) NZ586754A (fr)
PE (3) PE20140579A1 (fr)
PL (2) PL3401335T3 (fr)
PT (2) PT2238172T (fr)
RS (2) RS62085B1 (fr)
RU (3) RU2015101975A (fr)
SG (1) SG190607A1 (fr)
SI (2) SI2238172T1 (fr)
TW (1) TWI472339B (fr)
UA (1) UA104585C2 (fr)
WO (1) WO2009099829A1 (fr)
ZA (1) ZA201004898B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1771482T1 (sl) * 2004-07-22 2014-12-31 Genentech, Inc. Sestavek HER2 protitelesa
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1850874B1 (fr) * 2005-02-23 2013-10-16 Genentech, Inc. Extension de la periode menant à la progression de la maladie ou à la survie chez les patients atteints du cancer de l'ovaire par le pertuzumab
CN103432580A (zh) 2007-03-02 2013-12-11 健泰科生物技术公司 基于低her3表达预测对her二聚化抑制剂的响应
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2011084496A1 (fr) * 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anticorps anti-her2 et leurs utilisations
EP4328305A3 (fr) 2009-12-18 2024-08-14 CSL Ltd. Procede de purification de polypeptides
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
US9714294B2 (en) 2010-05-27 2017-07-25 Genmab A/S Monoclonal antibodies against HER2 epitope
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
JP2014514314A (ja) 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
SI2766040T1 (sl) 2011-10-14 2019-08-30 F. Hoffmann-La Roche Ag Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke
AU2012328322A1 (en) * 2011-10-27 2014-06-12 Genmab A/S Production of heterodimeric proteins
EP2793941A1 (fr) 2011-12-23 2014-10-29 F.Hoffmann-La Roche Ag Articles manufacturés et procédés destinés à la coadministration d'anticorps
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (fr) * 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
CA3071678A1 (fr) 2013-04-16 2014-10-23 Genentech,Inc. Variantes de pertuzumab et leur evaluation
TWI631132B (zh) * 2013-05-06 2018-08-01 賽諾菲公司 用於純化抗體之連續多步驟方法
WO2015051293A2 (fr) 2013-10-04 2015-04-09 Abbvie, Inc. Utilisation d'ions métalliques pour moduler les profils de glycosylation des protéines dans le cas de protéines recombinées
WO2015057910A1 (fr) 2013-10-16 2015-04-23 Oncobiologics, Inc. Formulations de tampon pour stabilité d'anticorps améliorée
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015127027A1 (fr) * 2014-02-20 2015-08-27 Wayne State University Compositions de polypeptides antigéniques her2, et leurs procédés d'utilisation pour le traitement et la prévention de carcinomes
EP3825327A1 (fr) 2014-03-11 2021-05-26 Molecular Templates, Inc. Protéines comportant des régions de liaison, des régions effectrices à sous-motifs a de shiga-toxine et des motifs de signal de localisation du réticulum endoplasmique carboxy-terminaux
MX2016011821A (es) 2014-03-11 2017-04-27 Molecular Templates Inc Proteinas que comprenden regiones efectoras de subunidad a de toxina shiga proximas a amino terminal y regiones de union de tipo inmunoglobulina de direccionamiento selectivo celular.
CA2946860A1 (fr) 2014-04-25 2015-10-29 Genentech, Inc. Methodes de traitement du cancer du sein precoce avec du trastuzumab-mcc-dm1 et du pertuzumab
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
EP3193940A1 (fr) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
AU2015314954B2 (en) 2014-09-12 2021-05-13 Genentech, Inc. Anti-HER2 antibodies and immunoconjugates
KR20170055521A (ko) 2014-09-17 2017-05-19 제넨테크, 인크. 항-her2 항체를 포함하는 면역콘주게이트
WO2016118707A1 (fr) * 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation de variants de charge dans une composition d'anticorps monoclonaux
LT3302551T (lt) 2015-05-30 2024-09-10 F. Hoffmann-La Roche Ag Anksčiau negydyto metastazavusio her2 teigiamo krūties vėžio gydymo būdai
LT3303373T (lt) 2015-05-30 2020-07-10 Molecular Templates, Inc. Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
KR20180030085A (ko) 2015-07-26 2018-03-21 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
EA037487B1 (ru) 2015-08-24 2021-04-02 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Биофармацевтические композиции
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
CA3010612A1 (fr) * 2016-01-08 2017-07-13 Oncobiologics, Inc. Procedes de separation des isoformes d'anticorps monoclonaux
US11285210B2 (en) 2016-02-03 2022-03-29 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
TW201827077A (zh) 2016-12-28 2018-08-01 美商建南德克公司 晚期her2表現癌症之治療
MA56006A (fr) 2017-01-17 2022-05-04 Hoffmann La Roche Formulations sous-cutanées d'anticorps her2
CN110418802A (zh) 2017-01-20 2019-11-05 朱诺治疗学有限公司 细胞表面缀合物及相关的细胞组合物和方法
US20200024312A1 (en) 2017-01-25 2020-01-23 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
AU2018258263A1 (en) 2017-04-24 2019-10-24 Genentech, Inc. ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
EP3796942A1 (fr) 2018-05-23 2021-03-31 ADC Therapeutics SA Adjuvant moléculaire
WO2020084503A1 (fr) * 2018-10-26 2020-04-30 Cadila Healthcare Limited Composition comprenant un anticorps ayant un niveau réduit de variants basiques de celui-ci
JP2022505144A (ja) * 2018-11-05 2022-01-14 中外製薬株式会社 Ｈｅｒ２ ｓ３１０ｆ特異的な抗原結合分子
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
EP4153130A1 (fr) 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG Utilisation de chélateurs pour la prévention de la formation de particules visibles dans des solutions de protéines parentérales
BR112022026888A2 (pt) 2020-06-29 2023-03-14 Genentech Inc Métodos de tratamento de câncer her2-positivo em um paciente, de terapia neoadjuvante de pacientes com câncer de mama inicial her2-positivo e de terapia neoadjuvante de câncer de mama inicial her2-positivo e método para tratar um paciente com câncer her2-positivo
EP4178529A1 (fr) 2020-07-07 2023-05-17 F. Hoffmann-La Roche AG Tensioactifs alternatifs utilisés en tant que stabilisants pour formulations de protéines thérapeutiques
WO2022013189A1 (fr) 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Dosages pour des combinaisons de doses fixes
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US533A (en) 1837-12-26 Truss for hermta
US4943A (en) 1847-01-26 Harness-buckle
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3934085A (en) 1984-01-30 1985-08-09 Icrf Patents Ltd. Improvements relating to growth factors
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1339946C (fr) 1987-03-31 1998-07-07 Michael J. Griffith Methode d'ultrapurification pour les polypeptides
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (fr) * 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
ES2106033T3 (es) 1989-05-19 1997-11-01 Genentech Inc Dominio extracelular de her2.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
WO1991003489A1 (fr) 1989-09-08 1991-03-21 The Johns Hopkins University Modifications structurelles du gene recepteur du facteur de croissance epidermique dans les gliomes humains
JP3208427B2 (ja) 1989-09-29 2001-09-10 オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (fr) 1991-05-14 1992-11-26 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993021319A1 (fr) 1992-04-08 1993-10-28 Cetus Oncology Corporation ANTICORPS HUMANISES SPECIFIES PAR C-erbB-2
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
EP0656064B1 (fr) 1992-08-17 1997-03-05 Genentech, Inc. Immunoadhesines bispecifiques
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
CA2103323A1 (fr) 1992-11-24 1994-05-25 Gregory D. Plowman Tyrosine kinase du recepteur her4 humain
WO1994022478A1 (fr) 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION DE TUMEURS AVEC DES ANTICORPS MONOCLONAUX DIRIGES CONTRE L'ONCOGENE $i(NEU)
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP0730646A1 (fr) 1993-11-23 1996-09-11 Genentech, Inc. TYROSINE KINASES PROTEIQUES APPELEES Rse
PT659439E (pt) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5808110A (en) 1994-07-21 1998-09-15 Akzo Nobel Nv Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP1241264A1 (fr) 1994-12-02 2002-09-18 Chiron Corporation Anticorps monoclonaux diriges contre des antigenes associes au carcinome du colon
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1110953B1 (fr) 1995-03-30 2009-10-28 Pfizer Products Inc. Dérivés de quinazolinone
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
EP2258726A1 (fr) 1995-06-14 2010-12-08 The Regents of the University of California Anticorps humains à haute affinité pour c-erbB-2
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
SI2275119T1 (sl) 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
JP2001504326A (ja) 1996-10-18 2001-04-03 ジェネンテック インコーポレーテッド 抗ＥｒｂＢ２抗体
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
SI0950067T1 (sl) * 1996-11-27 2007-12-31 Genentech Inc Afinitetno čiščenje polipeptida na proteinskemA matriksu
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP4327259B2 (ja) 1997-05-06 2009-09-09 ワイス・ホールディングズ・コーポレイション 多発性嚢胞腎の治療のためのキナゾリン化合物の使用
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
EP1028751B1 (fr) 1997-10-31 2008-12-31 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
HUP0004286A3 (en) 1997-11-06 2002-01-28 American Cyanamid Co Madison Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
PT1064027E (pt) 1998-03-27 2008-09-29 Genentech Inc Sinergismo de ligando de apo-2 e anticorpo anti-her-2
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DK1308456T3 (da) * 1998-05-06 2007-12-27 Genentech Inc Antistofoprensning ved ionbytterkromatografi
DK1308455T3 (da) * 1998-05-06 2006-07-31 Genentech Inc Sammensætning omfattende anti-HER2-antistoffer
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
IL143089A0 (en) 1998-11-19 2002-04-21 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
CA2374085C (fr) 1999-05-14 2015-12-29 Genentech, Inc. Traitement des tumeurs avec des anticorps anti erbb2
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) * 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
IL146954A0 (en) 1999-06-25 2002-08-14 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
ES2282120T3 (es) 1999-06-25 2007-10-16 Genentech, Inc. Tratamiento del cancer de prostata con anticuerpos anti-erbb2.
PL202369B1 (pl) 1999-08-27 2009-06-30 Genentech Inc Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
US20200048362A1 (en) 2000-03-16 2020-02-13 Immunogen, Inc. Methods of treatment using anti-erbb antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
CN101711868A (zh) 2000-05-19 2010-05-26 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
US6984494B2 (en) * 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
EP1300146A1 (fr) * 2001-10-03 2003-04-09 Boehringer Ingelheim International GmbH Preparation pharmaceutique pour le traitement des tumeurs mammaires animales
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030224397A1 (en) * 2002-02-11 2003-12-04 Genentech, Inc. Antibody variants with faster antigen association rates
US20050176740A1 (en) 2002-04-08 2005-08-11 Spector Neil L. Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
ES2401428T3 (es) 2002-04-10 2013-04-19 Genentech, Inc. Variantes de anticuerpos anti-HER2
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
EP2263691B1 (fr) * 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Traitement de cancer avec l'anti-erbb2 anticorps recombinant humanisé monoclonal (rhuMAb 2C4)
AU2003265994B2 (en) 2002-09-11 2010-04-01 Genentech, Inc. Protein purification
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
JP2006516117A (ja) 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
US20050025753A1 (en) * 2003-04-30 2005-02-03 Wei Han Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
EP1648940B1 (fr) * 2003-07-28 2016-04-27 Genentech, Inc. Reduction de la lixiviation de la proteine a lors de la chromatographie d'affinite sur la proteine a
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
EP2286844A3 (fr) 2004-06-01 2012-08-22 Genentech, Inc. Conjugués anticorps-médicament et procédés
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
SI1771482T1 (sl) * 2004-07-22 2014-12-31 Genentech, Inc. Sestavek HER2 protitelesa
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101115849A (zh) 2004-12-07 2008-01-30 健泰科生物技术公司 选择her抑制剂疗法的患者
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
EP1850874B1 (fr) * 2005-02-23 2013-10-16 Genentech, Inc. Extension de la periode menant à la progression de la maladie ou à la survie chez les patients atteints du cancer de l'ovaire par le pertuzumab
TW200642695A (en) 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
MY157955A (en) 2005-07-06 2016-08-30 Hoffmann La Roche Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AU2007259171A1 (en) 2006-06-05 2007-12-21 F. Hoffmann-La Roche, Ag Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
US20080050385A1 (en) 2006-08-21 2008-02-28 Thomas Friess Tumor therapy with an anti-vegf antibody
WO2008031531A1 (fr) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Thérapie antitumorale avec une combinaison d'anticorps anti-her2
CN103432580A (zh) 2007-03-02 2013-12-11 健泰科生物技术公司 基于低her3表达预测对her二聚化抑制剂的响应
EP1997534A1 (fr) 2007-05-31 2008-12-03 Pierre Fabre Medicament Thérapie de combinaison de traitement du cancer comportant de la vinflunine et trastuzumab
MX2009012838A (es) 2007-06-06 2009-12-11 Hoffmann La Roche Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.
WO2008154249A2 (fr) 2007-06-08 2008-12-18 Genentech, Inc. Marqueurs d'expression de gène de résistance tumorale à un traitement par inhibiteur her2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US20090053786A1 (en) 2007-07-09 2009-02-26 Yung-Hsiang Kao Prevention of disulfide bond reduction during recombinant production of polypeptides
MX338504B (es) 2007-09-12 2016-04-20 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
SI2215117T2 (en) 2007-10-30 2018-04-30 Genentech, Inc. Purification of the antibody by cation exchange chromatography
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
EP2260056A1 (fr) 2008-03-06 2010-12-15 Genentech, Inc. Polythérapie avec c-met et ses antagonistes
EP3692988A3 (fr) * 2008-03-18 2020-10-14 Genentech, Inc. Combinaisons d'un conjugué de médicament-anticorps anti-her2 et 5-fu, anticorps anti-vegf, carboplatin ou abt869 et procédés d'utilisation
US9235334B2 (en) 2008-05-09 2016-01-12 Genesis Industries, Llc Managing landbases and machine operations performed thereon
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010136569A1 (fr) * 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulateurs de la signalisation her2 chez des patients exprimant her2 souffrant d'un cancer de l'estomac
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
TW201129380A (en) 2009-12-04 2011-09-01 Genentech Inc Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
RU2013131232A (ru) 2010-12-09 2015-01-20 Дженентек, Инк. Лечение her2-позитивного рака при помощи паклитаксела и трастузумаба-mсc-dm1
JP6385060B2 (ja) 2011-03-07 2018-09-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 治療的に活性な抗体のインビボにおける選択
SI2766040T1 (sl) 2011-10-14 2019-08-30 F. Hoffmann-La Roche Ag Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke
EP2788500A1 (fr) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification de non-répondeurs aux inhibiteurs de her2
EP2793941A1 (fr) 2011-12-23 2014-10-29 F.Hoffmann-La Roche Ag Articles manufacturés et procédés destinés à la coadministration d'anticorps
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
CA3071678A1 (fr) 2013-04-16 2014-10-23 Genentech,Inc. Variantes de pertuzumab et leur evaluation
CA3056647A1 (fr) 2013-11-13 2015-05-21 Robert ARCH Anticorps specifiques du ligand 1a de type facteur de necrose tumorale et compositions ainsi qu'utilisations associees
KR102447878B1 (ko) 2013-12-17 2022-09-26 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
CA2946860A1 (fr) 2014-04-25 2015-10-29 Genentech, Inc. Methodes de traitement du cancer du sein precoce avec du trastuzumab-mcc-dm1 et du pertuzumab
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
JP6807186B2 (ja) 2016-08-24 2021-01-06 日本板硝子株式会社 サイドガラス
CN110505880A (zh) 2016-11-04 2019-11-26 基因泰克公司 Her2阳性乳腺癌的治疗
TW201827077A (zh) 2016-12-28 2018-08-01 美商建南德克公司 晚期her2表現癌症之治療
MA56006A (fr) 2017-01-17 2022-05-04 Hoffmann La Roche Formulations sous-cutanées d'anticorps her2
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
AU2018258263A1 (en) 2017-04-24 2019-10-24 Genentech, Inc. ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain
CN114392233A (zh) 2017-10-20 2022-04-26 生物技术公司 适用于治疗的脂质体rna制剂的制备和储存
BR112022026888A2 (pt) 2020-06-29 2023-03-14 Genentech Inc Métodos de tratamento de câncer her2-positivo em um paciente, de terapia neoadjuvante de pacientes com câncer de mama inicial her2-positivo e de terapia neoadjuvante de câncer de mama inicial her2-positivo e método para tratar um paciente com câncer her2-positivo
WO2022013189A1 (fr) 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Dosages pour des combinaisons de doses fixes
EP4259662A1 (fr) 2020-12-11 2023-10-18 Genentech, Inc. Polythérapies pour le traitement du cancer her2
TW202400230A (zh) 2022-03-14 2024-01-01 美商建南德克公司 乳癌的組合療法

Also Published As

Publication number Publication date
BRPI0905733B1 (pt) 2020-09-24
RU2543664C2 (ru) 2015-03-10
PL2238172T3 (pl) 2018-08-31
PE20091352A1 (es) 2009-09-16
CR20150625A (es) 2016-02-29
NZ586754A (en) 2012-08-31
HUE037471T2 (hu) 2018-09-28
ES2882041T3 (es) 2021-12-01
CL2009000178A1 (es) 2009-09-11
AU2009210545B2 (en) 2013-09-26
US20240262932A1 (en) 2024-08-08
CY1124500T1 (el) 2022-07-22
CA2711798A1 (fr) 2009-08-13
CA2711798C (fr) 2014-05-06
EP3401335B1 (fr) 2021-06-30
ES2668680T3 (es) 2018-05-21
PT2238172T (pt) 2018-05-15
TW200936162A (en) 2009-09-01
AR070276A1 (es) 2010-03-25
HUE055108T2 (hu) 2021-11-29
CN101981056B (zh) 2016-02-10
US20190322761A1 (en) 2019-10-24
IL206931A (en) 2015-10-29
DK2238172T3 (en) 2018-04-23
CO6231039A2 (es) 2010-12-20
CN101981056A (zh) 2011-02-23
CR11648A (es) 2010-10-05
IL241361A0 (en) 2015-11-30
SI3401335T1 (sl) 2021-11-30
RU2019134204A3 (fr) 2022-01-12
KR101223941B1 (ko) 2013-01-21
RU2019134204A (ru) 2021-04-26
US20220363780A1 (en) 2022-11-17
LT2238172T (lt) 2018-05-10
TWI472339B (zh) 2015-02-11
MX2010008035A (es) 2010-08-23
RU2010136029A (ru) 2012-03-10
US20230416401A1 (en) 2023-12-28
IL241361A (en) 2017-01-31
UA104585C2 (ru) 2014-02-25
RS57109B1 (sr) 2018-06-29
RS62085B1 (sr) 2021-08-31
MY158560A (en) 2016-10-14
JP5933179B2 (ja) 2016-06-08
RU2015101975A3 (fr) 2018-09-07
SG190607A1 (en) 2013-06-28
NO2238172T3 (fr) 2018-07-21
US11414498B2 (en) 2022-08-16
EP2238172B1 (fr) 2018-02-21
ECSP10010433A (es) 2010-09-30
HRP20180666T1 (hr) 2018-06-01
IL206931A0 (en) 2010-12-30
WO2009099829A1 (fr) 2009-08-13
US20140186867A1 (en) 2014-07-03
HK1151543A1 (zh) 2012-02-03
US8652474B2 (en) 2014-02-18
US9181346B2 (en) 2015-11-10
US20090202546A1 (en) 2009-08-13
US11597776B2 (en) 2023-03-07
US20170174785A1 (en) 2017-06-22
SI2238172T1 (en) 2018-05-31
ZA201004898B (en) 2011-09-28
RU2015101975A (ru) 2015-06-10
PL3401335T3 (pl) 2021-11-08
KR20100110379A (ko) 2010-10-12
AU2009210545A1 (en) 2009-08-13
HRP20211469T1 (hr) 2021-12-24
JP2014141499A (ja) 2014-08-07
PT3401335T (pt) 2021-07-23
EP4119583A1 (fr) 2023-01-18
EP2238172A1 (fr) 2010-10-13
LT3401335T (lt) 2021-09-10
US20140186343A1 (en) 2014-07-03
JP2011511780A (ja) 2011-04-14
DK3401335T3 (da) 2021-07-26
CY1120191T1 (el) 2018-12-12
PE20140579A1 (es) 2014-05-08
BRPI0905733A2 (pt) 2015-12-01
US12110341B2 (en) 2024-10-08
PE20190906A1 (es) 2019-06-26
AR116860A2 (es) 2021-06-23
BRPI0905733B8 (pt) 2021-05-25
EP3401335A1 (fr) 2018-11-14
AU2009210545C1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
MA32099B1 (fr) Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA33198B1 (fr) Anticorps anti-her di-spécifiques
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
MA30689B1 (fr) Derives de leptomycine
MA31821B1 (fr) Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
MA31984B1 (fr) Formulation d'anticorps
MA33811B1 (fr) Composés et méthodes utilisés pour la modulation kinases et indications à cet effet
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
ECSP088962A (es) Nuevos herbicidas
MA29427B1 (fr) Antagonistes et leurs methodes d'utilisation
BRPI0607240A2 (pt) derivados de maleimida, composições farmacêuticas e métodos para tratamento de cáncer
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
TNSN07398A1 (fr) Anticorps contre la p-cadherine
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MA33743B1 (fr) Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
NO20061412L (no) Terapi av okulaere foretyrrelser
MA29788B1 (fr) Combinaisons comprenant un inhibiteur des recepteurs vegf
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2